<DOC>
	<DOCNO>NCT00003034</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . It yet know whether Onconase plus doxorubicin effective doxorubicin alone treat patient malignant mesothelioma . PURPOSE : This randomized phase III trial study doxorubicin alone see well work compare doxorubicin Onconase treat patient malignant mesothelioma .</brief_summary>
	<brief_title>ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy doxorubicin without ranpirnase patient malignant pleural peritoneal mesothelioma . - Compare safety profile regimens patient . - Compare overall survival , progression-free survival , quality life patient treat regimen . OUTLINE : This randomize , open-label , control , multicenter study . Patients stratify accord disease histology ( epithelioid v nonepithelioid ) CALGB group 1-4 . Patients randomize 1 2 treatment arm . - Arm I : Patients receive ranpirnase IV 30 minute weekly follow doxorubicin IV . Treatment repeat every 3 week least 6 course absence disease progression . Patients demonstrate evidence clinical response stable disease may continue maintenance therapy ranpirnase single agent disease progression . - Arm II : Patients receive doxorubicin arm I 6 course . Quality life assess . PROJECTED ACCRUAL : A minimum 300 patient accrue study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Ranpirnase</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant pleural peritoneal mesothelioma Measurable evaluable disease CALGB group 14 No CNS metastases PATIENT CHARACTERISTICS : Age : 21 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC great 3,500/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : SGOT great 2 time upper limit normal Bilirubin great 2 mg/dL PT PTT normal Renal : Creatinine normal Cardiovascular : No symptomatic New York Heart Association class IIIV cardiovascular disease No congestive heart failure No angina pectoris No cardiac arrhythmia No uncontrolled hypertension No cerebrovascular disease Metabolic : No serum calcium , phosphate , electrolyte , metabolic abnormality , metabolic acidosis Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious infection No uncontrolled psychosis neurologic disease ( e.g. , seizure disorder ) No uncontrolled diabetes mellitus No primary malignancy within past 5 year except nonmelanoma skin cancer No senility emotional instability PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No one prior systemic chemotherapy regimen No prior doxorubicin At least 6 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy progressive recurrent disease allow except myocardium radiotherapy Surgery : Prior surgical resection allow</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
</DOC>